The Wall Street analyst predicted that SPECTRUM PHARMACEUTICALS’s share price could reach $4.00 by Mar 21, 2023. The average SPECTRUM PHARMACEUTICALS stock price prediction forecasts a potential upside of 284.62% from the current SPPI share price of $1.04.
Similarly, How high does IDEX go?
IDEX stock hit a 2022 high of $1.44 in early January and a low of $0.87 later in the same month. In 2021 its stock price ranged from 88 cents to $5.53. In an interview with Capital.com, Vinod Jain, senior analyst at Aite-Novarica Group, said “the stock could see more volatility due to its current price point”.
Should I invest in SPPI? The consensus among Wall Street equities research analysts is that investors should « buy » Spectrum Pharmaceuticals stock. View analyst ratings for Spectrum Pharmaceuticals or view top-rated stocks.
Thereof, Is SPPI good stock?
The financial health and growth prospects of SPPI, demonstrate its potential to underperform the market. It currently has a Growth Score of A. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of D.
Should I invest in Spectrum Pharmaceuticals stock?
Is Spectrum Pharmaceuticals stock A Buy? Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for stock to perform well in the short-term.
Is it good to buy IDEX stock?
Is IDEX a Good Stock to Buy? In my judgment, IDEX is a good stock to buy at current prices. It is relatively cheap compared to other EV car companies such as Nio and Tesla. In addition, it is racking up strategic partnerships along the way, making it a competitive player in a post-fossil-fuel-driven world.
Is IDEX undervalued?
PB vs Industry: IEX is overvalued based on its PB Ratio (5.3x) compared to the US Machinery industry average (2.4x).
Is Ideanomics a Chinese company?
IDEX Stock and the Chinese EV Business
But it’s important to remember what Ideanomics’ Chinese EV business is at the moment. It’s a reseller. It buys vehicles in bulk and sells them individually, earning a spread in the process.
Why is SPPI stock falling?
The big decline came after the company announced that the U.S. Food and Drug Administration turned down approval of Rolontis in treating neutropenia in patients receiving cancer drugs that decrease bone marrow activity.
Will Rolontis get approved?
Hanmi Pharm expects FDA nod for 2 drugs, to begin mRNA vaccine clinical trials. South Korea’s Hanmi Pharmaceutical is expected to receive FDA approval for « Rolontis », a treatment for neutropenia and “Poziotinib”, an anticancer drug this year.
Was Rolontis approved?
It is a long-acting biologic medicine to treat or prevent neutropenia in cancer patients receiving chemotherapy. Rolontis obtained the Ministry of Food and Drug Safety’s approval in March, becoming Hanmi’s first biologic drug and the nation’s 33rd novel drug.
Will Spectrum Pharmaceuticals stock go up?
Stock Price Forecast
The 5 analysts offering 12-month price forecasts for Spectrum Pharmaceuticals Inc have a median target of 4.00, with a high estimate of 10.00 and a low estimate of 3.00. The median estimate represents a +312.12% increase from the last price of 0.97.
Why is Spectrum Pharmaceuticals stock dropping?
Why Spectrum Pharmaceuticals Stock Is Crashing Today
The big decline came after the company announced that the U.S. Food and Drug Administration turned down approval of Rolontis in treating neutropenia in patients receiving cancer drugs that decrease bone marrow activity.
Does Ideanomics have a future?
Ideanomics is bordering on breakeven, according to some American Machinery analysts. They anticipate the company to incur a final loss in 2023, before generating positive profits of US$11m in 2024. The company is therefore projected to breakeven around 2 years from today.
Is IDEX a buy or sell?
IDEX has received a consensus rating of Buy. The company’s average rating score is 2.64, and is based on 7 buy ratings, 4 hold ratings, and no sell ratings.
Is IDEX a buy Zacks?
The company, with a $14.9-billion market capitalization, currently carries a Zacks Rank #2 (Buy). It is poised to benefit from a diversified business structure, strengthening end markets and buyouts in the quarters ahead.
Who is the owner of Ideanomics?
History. The company was founded in 2004 by Shane McMahon who currently also serves as the chairman. Alf Poor is the incumbent chief executive officer serving since February 2019.
Is Ideanomics an American company?
Ideanomics Capital leverages technology and innovation to improve efficiency, transparency, and profitability for the financial services industry. The company is headquartered in New York, NY, with global operations in the U.S., China, Ukraine, Malaysia, and UK.
Will Sppi get FDA approval?
–(BUSINESS WIRE)– Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Accelerated Approval of Beleodaq™ for the …
What does Spectrum Pharma do?
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development.
Join TheMoney.co community and don’t forget to share this post !